These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27859438)

  • 1. Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies.
    Goncalves J; Matos de Brito P; Batista A; Feio J; Machado F; Aperta J; Ascensão I; Pires V; Oliveira C; Armandina Pontes R; Alcobia A; Paulo Cruz J; Lampreia Guerreiro S; Farinha H; Margarida Freitas A; Caetano M; Almeida P; Costa B; Oliveira C; Campos C; Madureira B; Cavaco M; Catarino H;
    J Clin Pharm Ther; 2017 Apr; 42(2):239-243. PubMed ID: 27859438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
    Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
    J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update.
    Araújo FC; Sepriano A; Teixeira F; Jesus D; Rocha TM; Martins P; Tenazinha C; Cordeiro A; Mourão AF; Silva C; Vaz C; Duarte C; Ponte C; Dos Santos FP; Canhão H; Santos H; Pimentão JB; da Silva JC; Pereira J; da Silva JAP; Miranda LC; Oliveira M; Saavedra MJ; Gonçalves P; Falcão S; Capela S; Fonseca JE
    Acta Reumatol Port; 2017; 42(3):219-228. PubMed ID: 28894080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spanish Society of Hospital Pharmacy position paper on biosimilar medicines.
    Martínez-López de Castro N; Matilla-Fernández MB; Fraga-Fuentes MD; Mangues-Bafalluy I; Asensi-Díez R; Cajaraville-Ordoñana G
    Farm Hosp; 2018 Jul; 42(4):180-183. PubMed ID: 29959844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars in Dermatology: Current Situation (Part II).
    Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
    Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
    Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H; Lietzan E; Faccin F; Venema J
    Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biosimilars in the European Union: current situation and challenges].
    Wolff-Holz E; Weise M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1365-1372. PubMed ID: 33034693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory considerations in oncologic biosimilar drug development.
    Macdonald JC; Hartman H; Jacobs IA
    MAbs; 2015; 7(4):653-61. PubMed ID: 25961747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals.
    Pawłowska I; Pawłowski L; Krzyżaniak N; Kocić I
    BioDrugs; 2019 Apr; 33(2):183-191. PubMed ID: 30830647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody biosimilars: fears or opportunities?: First LabEx MAbImprove industrial workshop, May 28, 2013; Tours, France.
    Guillon-Munos A; Daguet A; Watier H
    MAbs; 2014; 6(4):805-9. PubMed ID: 24714167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars: Practical Considerations for Pharmacists.
    Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
    Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U; Hong S; Oh C; Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.